A multicenter, randomized, open-label phase 2b study to investigate the preliminary efficacy and safety of INNO-206 (Doxorubicin-EMCH) compared to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma

Trial Profile

A multicenter, randomized, open-label phase 2b study to investigate the preliminary efficacy and safety of INNO-206 (Doxorubicin-EMCH) compared to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Aldoxorubicin (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700249151) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
    • 07 Jun 2018 Results presented in the CytRx Corporation media release.
    • 08 Jun 2017 According to a CytRx Corporation media release, data from this and another study Phase 3 (CTP700214726) will be used in NDA filing for aldoxorubicin in soft tissue sarcomas (STS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top